Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study Reckamp, K. L., Akerley, W., Calvo, E., Clarke, J., Edelman, M. J., He, K., Moreno, V., Neal, J. W., Owonikoko, T. K., Patel, J. D., Patel, S. P., Riess, J. W., Sacher, A. G., Turcotte, S., Villaruz, L. C., Zauderer, M. G., Farsaci, B., Skoura, N., Chisamore, M., Johnson, M. L. OXFORD UNIV PRESS. 2019: 657-+
View details for Web of Science ID 000491295504252